Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has received a notice of allowance (NOA) from the US Patent and Trademark Office (USPTO) for its patent application that covers BL-1020 drug and its use as a treatment for the patients with schizophrenia.
Subscribe to our email newsletter
Prior to the NOA, BioLineRx has received approval for BL-1020 drug in Australia, Korea and China.
In pre-clinical and clinical trials, BL-1020 was effective at treating schizophrenia symptoms and showed a good safety profile.
BioLineRx CEO Kinneret Savitsky said they are pleased at receiving the notice of USPTO approval for the patent application covering BL-1020 and believe that the NOA represents significant further progress in the development and commercialization of BL-1020.